Abstract
The objectives of this study were to evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the prognostic factors influencing overall survival (OS). Patients with age < 85 years, ECOG-performance status (PS) < 3, and adequate renal, hepatic and hematologic function were eligible. NAB-P (125 mg/m2) and GEM (1000 mg/m2) day 1,8,15 every 4 weeks were employed for 3-6 cycles or until highest response. Overall, 147 cycles (median 4, range 1-11 cycles) were administered on thirty-seven consecutive patients (median 66 years old, range 40-82) treated. The median overall progression-free survival and OS were 6.2 and 9.2 months, respectively. The G 3-4 dose-limiting toxicity were neutropenia (20.7%), severe anemia (17.2%), and cardiovascular toxicity (10.3%). PS, number of cycles, baseline CA 19-9 and LDH serum levels, were found to be significantly related to OS. The multivariate analysis showed that both number of cycles (HR = 9.14, 95% CI 1.84-45.50, p = 0.001) and PS (HR = 13.18, 95% CI 2.73-63.71, p = 0.001) were independently associated with OS. NAB-P/GEM regimen should be used in all pa...Continue Reading
References
May 24, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C LouvetUNKNOWN GISCAD
Jun 1, 2005·The Lancet Oncology·Michele ReniValerio Di Carlo
Sep 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·William J GradisharJoyce O'Shaughnessy
Aug 22, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Volker HeinemannRalf Wilkowski
Apr 25, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Malcolm J MooreUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Jun 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard HerrmannUNKNOWN Central European Cooperative Oncology Group
Sep 4, 2008·Anti-cancer Drugs·Neil P DesaiWilliam J Gradishar
Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemMalcolm J Moore
Oct 28, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David CunninghamJohn P Neoptolemos
May 13, 2011·The New England Journal of Medicine·Thierry ConroyUNKNOWN PRODIGE Intergroup
Oct 5, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel D Von HoffManuel Hidalgo
Dec 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sophie Gourgou-BourgadeThierry Conroy
Oct 18, 2013·The New England Journal of Medicine·Daniel D Von HoffMarkus F Renschler
Feb 25, 2014·Clinics and Research in Hepatology and Gastroenterology·Alix PortalJulien Taieb
Mar 25, 2014·Journal of Medical Economics·Michele ReniMarc Botteman
Jun 29, 2014·BMC Cancer·Gillian K GreshamDerek J Jonker
Aug 6, 2014·PloS One·Qin LiBangwei Cao
Citations
Jul 4, 2015·Langenbeck's Archives of Surgery·Stephanie E Combs
Dec 18, 2015·Apoptosis : an International Journal on Programmed Cell Death·Zhezhu HanJoo-Hang Kim
Apr 20, 2016·Oncotarget·Weiwei ShengQi Dong
Jan 7, 2017·BMC Cancer·Yuanyuan XiaoNaiqing Zhao
Nov 8, 2018·Gut and Liver·Min Su YouYong-Tae Kim
Nov 8, 2020·Scientific Reports·Giandomenico RovielloEnrico Mini
Dec 1, 2018·BMC Cancer·Ana FernándezAlberto Carmona-Bayonas
Jan 10, 2019·BMC Cancer·Hakon BlomstrandNils O Elander
Sep 23, 2020·Current Cancer Drug Targets·Martina CatalanoMonica Ramello